Catalyst Event

AbbVie Inc (ABBV) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

6/10/2026, 12:00:00 AM

OtherSentiment: Negative

AbbVie received a Complete Response Letter (CRL) from the U.S. FDA on June 10, 2026, for its fast-acting neurotoxin, TrenibotE, for glabellar lines. A price impact of ≥10% is estimated due to the significant delay in a major product launch, expected.

Korean Translation

애브비, 2026년 6월 10일 미국 FDA로부터 미간 주름 츘료제인 석효성 뉴로톡신 트레니보트E(TrenibotE)에 대해 보완요구서한(CRL)을 수령함. 주요 신약 출시 지연에 따라 10% 이상의 가격 영향이 예상됨.

Related Recent Events

View Full Timeline